Drug Development Pharma - December 7, 2017
InDex Pharmaceuticals announces new scientific data
InDex Pharmaceuticals Holding has announced new scientific data on the mechanism of action of cobitolimod, the company’s lead drug candidate. The findings show that cobitolimod can modulate the immune system in ulcerative colitis by balancing the mucosal Th17/Treg cell response. Cobitolimod has demonstrated clinical efficacy and a favourable safety profile in inducing clinical remission in […]
Intellectual Property - October 11, 2017
New patent for InDex Pharmaceuticals
InDex Pharmaceuticals Holding announces that a new method of use patent for the drug candidate cobitolimod will be issued by the United States Patent and Trademark Office (USPTO). The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not […]
Intellectual Property - September 13, 2017
Index Pharmaceuticals granted patent in Japan
The company announces that a new method of use patent for the drug candidate cobitolimod has been granted by the Japan Patent Office. The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy. […]
Clinical Trials - June 26, 2017
InDex Pharmaceuticals enrolls first patient in Phase IIb study
InDex Pharmaceuticals Holding announces that the first patient has been enrolled in the clinical study CONDUCT, a phase IIb dose optimisation study with the drug candidate cobitolimod. Cobitolimod is an immunotherapeutic, which is being developed for the treatment of moderate to severe active ulcerative colitis. The CONDUCT study will include 215 patients with left-sided moderate […]
Intellectual Property - March 14, 2017
InDex Pharmaceuticals granted patent in the US
InDex Pharmaceuticals Holding announces that a patent covering 19 compounds from the company’s DIMS platform has been granted by the United States Patent and Trademark Office (USPTO). InDex has a discovery stage portfolio of more than 150 DNA-based ImmunoModulatory Sequences (DIMS), several of which are already protected by approved composition-of-matter patents. The new US patent, […]
Agreement - February 1, 2017
InDex Pharmaceuticals enters agreement
InDex Pharmaceuticals Holding has entered an agreement for services with the global contract research organization (CRO) PAREXEL for the implementation of the CONDUCT study. The CONDUCT is a phase IIb dose optimisation study with the drug candidate cobitolimod for the treatment of moderate to severe active ulcerative colitis. According to the agreement, the first patient […]
